Shares of Hinge Health Inc. (NYSE:HNGE - Get Free Report) have earned an average recommendation of "Buy" from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. Thirteen research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $46.00.
A number of equities research analysts recently weighed in on the stock. Evercore ISI began coverage on shares of Hinge Health in a report on Monday, June 16th. They set an "outperform" rating and a $50.00 price objective for the company. Raymond James Financial started coverage on Hinge Health in a report on Monday, June 16th. They issued an "outperform" rating and a $45.00 price target for the company. Morgan Stanley started coverage on Hinge Health in a research note on Monday, June 16th. They issued an "overweight" rating and a $46.00 price objective on the stock. Truist Financial assumed coverage on Hinge Health in a research report on Monday, June 16th. They set a "buy" rating and a $48.00 target price for the company. Finally, Piper Sandler initiated coverage on Hinge Health in a report on Monday, June 16th. They issued an "overweight" rating and a $41.00 target price for the company.
Get Our Latest Analysis on HNGE
Hinge Health Stock Down 1.2%
Shares of HNGE opened at $44.28 on Friday. Hinge Health has a 12-month low of $33.42 and a 12-month high of $52.16.
Hinge Health Company Profile
(
Get Free ReportOur vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
